Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anti-Microbialvior BioteQ Co (ROCO:6864) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anti-Microbialvior BioteQ Co EBITDA Margin % Related Terms
Anti-Microbialvior BioteQ Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anti-Microbialvior BioteQ Co EBITDA Margin % Chart
ROCO:6864 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anti-Microbialvior BioteQ Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anti-Microbialvior BioteQ Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anti-Microbialvior BioteQ Co (ROCO:6864) has a EBITDA Margin % of -10,107.21% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anti-Microbialvior BioteQ Co and its competitors. According to the industry distribution chart, Anti-Microbialvior BioteQ Co ranks #881 out of 939 companies in the Biotechnology industry, placing it in the top 93.8%.
Is Anti-Microbialvior BioteQ Co's EBITDA Margin % too high?
Anti-Microbialvior BioteQ Co's current EBITDA Margin % is -10,107.21%. Based on the distribution chart, Anti-Microbialvior BioteQ Co ranks #881 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anti-Microbialvior BioteQ Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anti-Microbialvior BioteQ Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anti-Microbialvior BioteQ Co ranks #881 out of 939 companies for EBITDA Margin %. This places Anti-Microbialvior BioteQ Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anti-Microbialvior BioteQ Co and its competitors. Anti-Microbialvior BioteQ Co's current EBITDA Margin % is -10,107.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anti-Microbialvior BioteQ Co stock overvalued right now?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co (ROCO:6864) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.49, compared to a current price of NT$42.90 — trading 68.3% above its estimated fair value. The current EBITDA Margin % is -10,107.21%. Anti-Microbialvior BioteQ Co's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anti-Microbialvior BioteQ Co (ROCO:6864), the current EBITDA Margin % is -10,107.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anti-Microbialvior BioteQ Co (ROCO:6864) Overvalued in 2026?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co stock appears to be overvalued.
The current stock price of NT$42.90 is trading 68.3% above its estimated GF Value™ of NT$25.49.
GuruFocus considers Anti-Microbialvior BioteQ Co to be Significantly Overvalued.
Key valuation signals for ROCO:6864:
EBITDA Margin %: -10,107.21%
GF Value™: NT$25.49 vs. price of NT$42.90 (68.3% above fair value)
No single metric tells the full story. See the ROCO:6864 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6864 has been successfully added to your 
